spacer
home > ict > autumn 2018 > reviewing the rulebook
PUBLICATIONS
International Clinical Trials

Reviewing the Rulebook

Most clinical trials companies have gone through detailed exercises to put the data processing into proper framework: carrying inventories, creating the records of personal data processing activities, going through data protection impact assessments, appointing data protection officers, performing training sessions for staff, etc. Companies have been anxious that this could be a big change in clinical trials, as data no longer belongs to those processing it, personal data could be pulled at any time, and any noncompliance will be severely punished.

This article will take one more look at the regulation, revisit more talked about terms, explore potential changes for data management, and see if any rules are in place for electronic data capture (EDC) systems per the new regulation.

About the New Regulation

The EU General Data Protection Regulation (GDPR) 2016/679 became effective in all EU countries (plus Iceland, Liechtenstein, and Norway) as of May 25 2018, repealing the Data Protection Directive (effective since 1995). The main goal of the regulation is to strengthen the protection of an individual’s personal data, meaning a person should know what data is being collected about them, for what purpose, and where it is being processed (eg, in case it is transferred outside of the EU). Per the GDPR, any processing of personal data in the context of the activities of a controller or a processor in the EU should be carried out in accordance with this regulation, regardless if the processing takes place in the EU or not. As a maximum punishment for failure to comply, the fines can be as high as EUR €20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year. Any data breach must be reported within 72 hours upon becoming aware of it, unless it is demonstrably unlikely to cause risks to the rights and freedoms of data subjects (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Kaia Koppel is an Associate Director in the data science and documentation services department at KCR. Gaining her experience in clinical trials, Kaia worked in a top pharmaceutical company in the UK and CROs based in Estonia and Germany. In her current role, she is responsible for assuring full study support, from design and set-up through to conducting the trial until the successful closeout. Kaia is also actively involved in developing data management procedures within the company and supporting other departments in implementing new innovative technological solutions. She also holds a Master’s degree in social sciences.

Agnieszka Felicjanczuk is a Legal Counsel at KCR. Agnieszka has over 10 years’ experience in legal affairs, providing advice and expertise across much of Europe as well as the US. She has a wealth of experience in contracts negotiation and legal advice provision in clinical trials. In her current role, Agnieszka is responsible for providing legal advice related to business operations of KCR across various jurisdictions, contracts negotiation, and corporate matters. She is actively involved in ensuring GDPR compliance at KCR.
spacer
Kaia Koppel
spacer
spacer
spacer
Agnieszka Felicjanczuk
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement